Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Update on hepatitis B virus infection.World J Gastroenterol. 2014; 20: 13293-13305
- Hepatitis B: the virus and disease.Hepatology. 2009; 49: S13-S21
- Hepatitis B virus genotypes: global distribution and clinical importance.World J Gastroenterol. 2014; 20: 5427-5434
- Lamivudine in hepatitis B-associated membranous nephropathy.Kidney Int. 2005; 68: 1750-1758
- Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane.Lancet. 1971; 2: 234-237
- Membranous nephropathy related to hepatitis B virus in adults.N Engl J Med. 1991; 324: 1457-1463
- Hepatitis B and renal disease.Curr Hepat Rep. 2010; 9: 99-105
- Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy.Clin Nephrol. 2012; 78: 456-464
- Hepatitis B virus-associated glomerulonephritis in children.in: Murakami K. Kitagawa T. Yabuta K. Recent advances in pediatric nephrology. Excerpta Medica, New York1987
- Free "small" and IgG-associated "large" hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis.N Engl J Med. 1979; 300: 814-819
- Deposition of hepatitis B e antigen in membranous glomerulonephritis: identification by F(ab')2 fragments of monoclonal antibody.Kidney Int. 1984; 26: 338-341
- The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies.Clin Nephrol. 1979; 12: 109-116
- Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases.Am J Pathol. 1978; 90: 619-632
- IgA nephropathy associated with hepatitis B virus antigenemia.Nephron. 1987; 47: 141-143
- Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon.Am J Nephrol. 1997; 17: 112-117
- Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations.Kidney Int. 1990; 37: 663-676
- In situ immune complex formation and glomerular injury.Kidney Int. 1980; 17: 1-13
- Pathogenesis of membranous nephropathy.Annu Rev Med. 1988; 39: 517-530
- Biochemical and serological characteristics of children with membranous nephropathy due to hepatitis B virus infection: correlation with hepatitis B e antigen, hepatitis B DNA and hepatitis D.Nephron. 1988; 49: 184-189
- Hepatitis B e antigen-mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HBeAg in the serum and glomeruli.Lab Invest. 1981; 44: 214-220
- Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease.Am J Gastroenterol. 2005; 100: 972-976
- Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.Am J Nephrol. 2015; 41: 345-353
- Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life.Hepatology. 1986; 6: 962-965
- Hepatitis B virus-associated nephropathy.Am J Nephrol. 2004; 24: 198-211
- Treatment of hepatitis B virus-associated nephropathy in black children.Pediatr Nephrol. 2002; 17: 393-399
- HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy.Tissue Antigens. 1998; 52: 130-134
- Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis.Clin Nephrol. 2008; 70: 69-71
- Treatment of hepatitis B virus-associated membranous nephropathy: lamivudine era versus post-lamivudine era.Korean J Intern Med. 2012; 27: 394-396
- Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa.Gastroenterology. 1995; 109: 540-546
- Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon.Kidney Int. 1995; 47: 225-230
- Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection.Can J Gastroenterol. 2005; 19: 625-629
- Hepatitis B virus-associated nephropathy: an International Data Analysis.Iran J Kidney Dis. 2010; 4: 101-105
- Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis.Aliment Pharmacol Ther. 2006; 24: 781-788
- Antiviral treatment for chronic hepatitis B virus infection–immune modulation or viral suppression?.Neth J Med. 2006; 64: 175-185
- Management of hepatitis B: 2000–summary of a workshop.Gastroenterology. 2001; 120: 1828-1853
- A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med. 2006; 354: 1001-1010
- Management of hepatitis B: consensus of the Japan Society of Hepatology 2009.Hepatol Res. 2011; 41: 1-21
- The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication.Am J Transl Res. 2016; 8: 1593-1600
- The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia.Nephron. 1990; 54: 12-17
- Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form.Clin Nephrol. 2000; 54: 161-163
- Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy.Virchows Arch A Pathol Anat Histopathol. 1989; 414: 279-284
- 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides.Arthritis Rheum. 2013; 65: 1-11
- Infections in vasculitis.Best Pract Res Clin Rheumatol. 2013; 27: 19-31
- Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults.Kidney Int Suppl. 1991; 35: S40-S45
- Hepatitis associated antigen and periarteritis nodosa (PAN).Vox Sang. 1970; 19: 410-411
- Hepatitis B antigen-associated periarteritis nodosa in patients undergoing long-term hemodialysis.Am J Med. 1980; 68: 86-90
- Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome.Lupus. 1998; 7: 238-258
- Polyarteritis nodosa.Tech Vasc Interv Radiol. 2014; 17: 247-251
- Diagnosis and classification of polyarteritis nodosa.J Autoimmun. 2014; 48-49: 84-89
- Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.Arthritis Rheum. 2010; 62: 616-626
- Polyarteritis nodosa-induced pancreaticoduodenal artery aneurysmal rupture.Int J Angiol. 2015; 24: 63-66
- Immunology of hepatitis B virus infections.Rheumatol Int. 1989; 9: 167-173
- The rheumatic manifestations of infection with the human immunodeficiency virus.Semin Arthritis Rheum. 1989; 18: 225-239
- The infectious etiology of vasculitis.Autoimmunity. 2009; 42: 432-438
- Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis.J Autoimmun. 2001; 16: 269-274
- Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients.Medicine. 1995; 74: 238-253
- Polyarteritis nodosa: a contemporary overview.Autoimmun Rev. 2016; 15: 564-570
- Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome–62 patients.J Rheumatol. 1993; 20: 1345-1349
- Hepatitis B and immune-complex disease.N Engl J Med. 1984; 310: 43-46
- The challenge of managing patients with polyarteritis nodosa.Curr Opin Rheumatol. 2007; 19: 33-38
- Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients.Medicine. 2005; 84: 313-322
- Therapeutic strategies for systemic necrotizing vasculitides.Allergol Int. 2007; 56: 105-111
- Therapeutic immunomodulation in systemic vasculitis: taking stock.Joint Bone Spine. 2013; 80: 374-379
- EULAR recommendations for the management of primary small and medium vessel vasculitis.Ann Rheum Dis. 2009; 68: 310-317
- Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients.Ann Med Interne (Paris). 1992; 143: 63-74
- Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients.J Rheumatol. 1993; 20: 289-298
- Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa.Arthritis Rheum. 2004; 51: 482-487
- HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir.Kidney Blood Press Res. 2014; 39: 65-73
- Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis.Ann Intern Med. 2008; 149: 912-913
- Vasculitides secondary to infections.Clin Exp Rheumatol. 2006; 24: S71-S81
- Vasculitis related to viral and other microbial agents.Best Pract Res Clin Rheumatol. 2015; 29: 226-243
Division of Viral Hepatitis and National Center for HIV/AIDS VH S, and TB Prevention., Surveillance for Viral Hepatitis - United States, 2015. 2015. Available at: https://www.cdc.gov/hepatitis/statistics/2015surveillance/commentary.htm. Accessed June 19, 2017.
- Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.J Immunol. 2002; 169: 3447-3458
- Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.Lancet. 1997; 349: 825-832
- Cryoglobulins.J Clin Pathol. 2002; 55: 4-13
- Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases..Seminars in hematology. 1991; 28: 79-94
- The cryoglobulins: an overview.Eur J Clin Invest. 2001; 31: 628-638
- Hyperproteinemia associated with multiple myeloma: with report of case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease.Bull Johns Hopkins Hosp. 1933; 52: 156-165
- Cryoglobulinemia based on interaction between a gamma macroglobulin and 7S gamma globulin.Am J Med. 1962; 32: 142-147
- Hepatitis C virus infection and glomerulonephritis. vol. 20. Oxford University Press Inc, New York1996
- Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C.J Viral Hepat. 2000; 7: 138-143
- Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center.Medicine. 2001; 80: 252-262
- Hepatitis C virus associated glomerulopathies.World J Gastroenterol. 2014; 20: 7544-7554
- Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.Kidney Int. 1998; 54: 650-671
- Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases.J viral Hepat. 2000; 7: 23-29
- Glomerular disease associated with hepatitis C virus infection in native kidneys.Nephrol Dial Transplant. 2000; 15: 28-33
- Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis.Kidney Int. 1988; 34: 109-116
- Renal involvement in essential mixed cryoglobulinemia.Kidney Int. 1989; 35: 1004-1014
- Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.Seminars in arthritis and rheumatism. 2004; 33: 355-374
- Hepatitis C virus associated membranous glomerulonephritis.Clin Nephrol. 1995; 44: 141-147
- Hepatitis C virus-associated glomerulonephritis. Effect of α-interferon therapy.Kidney Int. 1994; 46: 1700-1704
- Fibrillary glomerulonephritis associated with hepatitis C viral infection.Am J Kidney Dis. 1997; 29: 132-135
- Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy.J Am Soc Nephrol. 1998; 9: 2244-2252
- Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features.Kidney Int. 2003; 63: 1450-1461
- Immunotactoid glomerulopathy (ITGP): a not fully defined clinicopathologic entity.Ren Fail. 1993; 15: 401-405
- Fibrillary renal deposits and nephritis.Am J Pathol. 1983; 113: 279
- Fibrillary glomerulonephritis: an entity with unusual immunofluorescence features.Kidney Int. 1987; 31: 781-789
- Clinical and pathologic features of fibrillary glomerulonephritis.Kidney Int. 1992; 42: 1401-1407
- Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors.Lab Invest. 1993; 69: 714-723
- Membranoproliferative glomerulonephritis associated with hepatitis C virus infection.N Engl J Med. 1993; 328: 465-470
- Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.N Engl J Med. 1994; 330: 751-756
- Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.Blood. 1997; 90: 3865-3873
- Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial.Blood. 1993; 81: 1132-1136
- Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection.J Rheumatol. 2001; 28: 2466-2473
- Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.J Hepatol. 2005; 42: 632-638
- Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med. 2004; 140: 346-355
- Treatment of hepatitis C virus-related systemic vasculitis.J Rheumatol. 2005; 32: 2078-2082
- Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study.Blood. 2010; 116: 343-353
- Interferon-α and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitis.Arthritis Rheumatol. 2002; 46: 3317-3326
- PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitis.Arthritis Rheumatol. 2005; 52: 911-915
- Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study.Arthritis Rheumatol. 2006; 54: 3696-3706
- Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN.Am J Kidney Dis. 2004; 43: 617-623
- Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.Nephrol Dial Transplant. 2003; 18: 1573-1580
- Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20.Blood. 2003; 101: 3818-3826
- Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.Leuk Lymphoma. 2003; 44: 1951-1955
- Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.Nephrol Dial Transplant. 2004; 19: 3054-3061
- Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.Rheumatology. 2006; 45: 842-846
- PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.J Hepatol. 2015; 62: 24-30
- Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.Ann Rheum Dis. 2008; 67: 1431-1436
- Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?.Ann Rheum Dis. 2008; 67: 283-287
- Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C–related mixed cryoglobulinemia.Blood. 2010; 116: 326-334
- A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.Arthritis Rheumatol. 2012; 64: 843-853
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitis.Arthritis Rheumatol. 2012; 64: 835-842
- KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.Am J Kidney Dis. 2008; 52: 811-825
AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. Available at: http://www.hcvguidelines.org. Accessed July 2, 2017.
- Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease.Gastroenterology. 2016; 150: 1590-1598
- EXPEDITION-IV: safety and efficacy of GLE/PIB in adults with renal impairment and Chronic Hepatitis C Virus Genotype 1 – 6 Infection.Hepatology. 2016; 64: 1125A
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.Lancet. 2015; 386: 1537-1545
- Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.Liver Int. 2016; 36: 807-816
- Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.J Hepatol. 2015; 63: 763-765
- Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR< 30 ml/min.Liver Int. 2016; 36: 798-801
- Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Liver Int. 2017; 37: 974-981
- Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.N Engl J Med. 2015; 373: 2599-2607
- Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis.Gastroenterology. 2017; 153: 49-52.e5
- Efficacy and safety of direct acting antivirals for the treatment of mixed cryoglobulinemia.Am J Gastroenterol. 2017; 112: 1298-1308
- Virologic, clinical, and immune response outcomes of patients with hepatitis C virus–associated cryoglobulinemia treated with direct-acting antivirals.Clin Gastroenterol Hepatol. 2017; 15: 575-583.e1
- FRI-216-Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life.J Hepatol. 2017; 66: S505
- Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study.Curr Drug Targets. 2017; 18: 772-785
- Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.Ann Rheum Dis. 2016; 75: 1777-1782
- Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis c virus–induced cryoglobulinemia vasculitis.Gastroenterology. 2017; 152: 2052-2062.e2
- Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: a multi center open label study.Dig Liver Dis. 2017; 49: e32
- Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.Hepatology. 2016; 64: 1473-1482
- Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents.Hepatology. 2016; 63: 408-417
- FRI-265-Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia.J Hepatol. 2017; 66: S528-S529
- Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy.Rheumatology. 2016; 55: 2084-2085
- Effectiveness and cost of hepatitis C virus cryoglobulinemia vasculitis treatment: from interferon-based to direct acting antivirals era.Liver Int. 2017; 37: 1805-1813
- Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series.Postgrad Med. 2015; 127: 413-417
- Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.Dig Liver Dis. 2014; 46: 833-837
KDIGO. KDIGO 2017 clinical practice guideline on the prevention, diagnosis, evaluation and treatment of hepatitis C in CKD. 2017. Accessed February 8, 2017. Available at: https://kdigo.org/clinical_practice_guidelines/Hep%20C/KDIGO%202017%20Hep%20C%20GL%20Public%20Review%20Draft%20FINAL.pdf
- Interferon treatment on glomerulonephritis associated with hepatitis C virus.Pediatr Nephrol. 2000; 15: 271-273
- Successful interferon-α treatment in a patient with IgA nephropathy associated with hepatitis C virus infection.Intern Med. 2010; 49: 2531-2532
- Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.Lancet HIV. 2016; 3: e361-e387
- HIV and the spectrum of human disease.J Pathol. 2015; 235: 229-241
WHO. Number of deaths due to HIV. 2018. Available at: http://www.who.int/gho/hiv/epidemic_status/deaths/en/. Accessed April 18, 2018.
- Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med. 1998; 338: 853-860
- HIV infection and the risk of acute myocardial infarction.JAMA Intern Med. 2013; 173: 614-622
- Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease.Arch Intern Med. 2011; 171: 737-743
- Metabolic syndrome in HIV-positive patients.HIV & AIDS Review. 2015; 14: 35-41
- Kidney disease in patients with HIV infection and AIDS.Clin Infect Dis. 2008; 47: 1449-1457
- The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis.AIDS. 2015; 29: 1061-1066
- Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity.AIDS. 2015; 29: 941-946
- HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.Nat Rev Nephrol. 2015; 11: 150-160
- Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome.N Engl J Med. 1984; 310: 669-673
- Case 12-2017-A 34-year-old man with nephropathy.N Engl J Med. 2017; 376: 1575-1585
- Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.Nephrol Dial Transplant. 2015; 30: 1734-1740
- Presentation of HIV-associated nephropathy and outcome in HAART-treated patients.Nephrol Dial Transplant. 2012; 27: 1114-1121
- Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.J Clin Invest. 1997; 100: 84-92
- APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.J Am Soc Nephrol. 2011; 22: 2129-2137
- APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.J Am Soc Nephrol. 2011; 22: 1991-1996
- Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study.AIDS. 2004; 18: 541-546
- Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.J Am Soc Nephrol. 2005; 16: 2412-2420
- HIV-associated kidney glomerular diseases: changes with time and HAART.Nephrol Dial Transplant. 2012; 27: 2349-2355
- Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Clin Infect Dis. 2014; 59: e96-e138
- Antiretroviral therapy in the treatment of HIV-associated nephropathy.Nephrol Dial Transplant. 2006; 21: 2809-2813
- Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy.J Am Soc Nephrol. 1997; 8: 1140-1146
- Predictors of renal outcome in HIV-associated nephropathy.Clin Infect Dis. 2008; 46: 1282-1289
- Outcomes of kidney transplantation in HIV-infected recipients.N Engl J Med. 2010; 363: 2004-2014
- Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy.Clin J Am Soc Nephrol. 2013; 8: 1524-1532
- The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.Kidney Int. 2004; 66: 1145-1152
- Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.J Acquir Immune Defic Syndr. 2004; 35: 269-273
- Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.Antivir Ther. 2006; 11: 79-86
- Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.Kidney Int. 2010; 78: 1171-1177
- Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study.J Acquir Immune Defic Syndr. 2016; 71: 530-537
- Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.PLoS One. 2013; 8: e77268
- Atazanavir crystal nephropathy.AIDS. 2007; 21: 2357-2358
- HIV medication-based urolithiasis.Clin Kidney J. 2014; 7: 121-126
- Results of lamivudine trials in Asia.J Hepatol. 2003; 39: S111-S115
- Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy.J Nippon Med Sch. 2013; 80: 387-395
Article info
Publication history
Published online: September 07, 2018
Footnotes
Disclosures: S.M. Rutledge and J.D. Long have no conflicts of interest to declare and no grants or other funding to disclose. M.E. Sise has received grant support from Gilead Sciences (GS-US-337-4063), Abbvie, and Merck & Co. She has participated in scientific advisory board meetings for Abbvie and Merck & Co and is a Scientific Consultant to Abbvie.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
